SPONSOR: �transgene Statistical Analysis Plan (SAP) Final Version 3.0 / 13 November 2019 CONFIDENT IAL A PHASE II STUDY EVALUATING THE EFFICACY AND THE SAFETY OF FIRST-LINE CHEMOTHERAPY COMBINED WITH TG4010 AND NIVOLUMAB IN PATIENTS WITH ADV ANCED NON-SQU AMOUS NON-SMALL-CELL LUNG CANCER (NSCLC) Study phase: II PROTOCOL N° TG4010.24 EUDRACT N° 2016-005115-41 IND N° 8559 NCT03353675 Transgene Boulevard Gonthier d'Andemach Parc d'innovation -CS80166 67405 Illkirch Graffenstaden Cedex -FRANCE The confidential information contained in this document is the property ofTransgene. lt is provided to you in confidence, for review by you, your staff, regulatory authorities, and members of ethics commiltees or institutional review boards. lt is understood that this information will not be disclosed to any other third party, in any form, without prior authorization from Transgene, except to the extent necessary to obtain the written informed consent from the persons to whom the Investigational Medicinal Product may be administered.